이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PuraPharm 배당금

배당금 기준 확인 0/6

PuraPharm 현재 배당금을 지급하지 않습니다.

주요 정보

배당 수익률

지급 비율

업계 평균 수익률	3.5%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	HK$0.0202
주당 순이익	-HK$0.22
배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 1498 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: 1498 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

PuraPharm 시장 대비 배당 수익률

1498 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (1498)	0%
시장 하위 25% (HK)	3.3%
시장 상위 25% (HK)	8.1%
업계 평균 (Pharmaceuticals)	3.5%
애널리스트 예측 (1498) (최대 3년)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 1498 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 1498 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 1498 Hong Kong 시장에서 주목할만한 배당금을 지급하지 않습니다.

주주에 대한 현금 배당금

현금 흐름 범위: 1498 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

PuraPharm 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

First half 2024 earnings released: HK$0.047 loss per share (vs HK$0.095 loss in 1H 2023)

PuraPharm Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

PuraPharm Corporation Limited to Report First Half, 2024 Results on Aug 28, 2024

PuraPharm Corporation Limited has withdrawn its Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited has filed a Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Purapharm Corporation Limited Announces Retirement of Non-Executive Director

Full year 2021 earnings released: HK$0.31 loss per share (vs HK$0.086 profit in FY 2020)

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Investor sentiment improved over the past week

Founder recently bought HK$86k worth of stock

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

CFO & Company Secretary Ka Kuen Lau has left the company

Independent Non-Executive Director Kin Keung Chan has left the company

Executive Vice-Chairman Kam Biu Tsoi has left the company

Non-Executive Director Kin Man Chan has left the company

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day high: HK$0.80

New 90-day high: HK$0.78

Founder recently bought HK$54k worth of stock

New 90-day low: HK$0.66

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

PuraPharm Corporation Limited Appoints Norimoto Hisayoshi as Executive Director, Effect from 17 November 2020

First half earnings released

Founder recently sold HK$9.5m worth of stock

New 90-day high - HK$0.80

Earnings released

PuraPharm Corporation Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.60

결제의 안정성과 성장

시장 대비 배당 수익률

주주에 대한 수익 배당금

주주에 대한 현금 배당금

강력한 배당금 지급 기업 알아보기